U.S. markets closed

Volatility Is Here To Stay

Daniel Laboe

The past 8 trading days have experienced 1,000+ point Dow swings, and the VIX (the fear index) closed at 82.69 on Monday (March 16th), its highest level in history. The length and extent of this pandemic effects are still highly ambiguous.

The markets have priced in a recession with the S&P 500 roughly 30% off its highs. Analysts are anticipating significant GDP declines for at least the first two quarters of 2020 and could extend into Q3.

One thing is clear: the market volatility will remain until this virus is under control. Fund managers and analysts are now anticipating a U-shaped recovery, a change from the rapid V-shaped recovery that was initially expected.

As a long-term investor, I am beginning to buy discounted equities with caution. Price-averaging down on all the red days. I am slowly adding positions in stocks like Adobe ADBE, Facebook FB, Microsoft MSFT, and Disney DIS.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Microsoft Corporation (MSFT) : Free Stock Analysis Report
 
The Walt Disney Company (DIS) : Free Stock Analysis Report
 
Adobe Systems Incorporated (ADBE) : Free Stock Analysis Report
 
Facebook, Inc. (FB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research